Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07390643 · ClinicalTrials.gov registry record · NA
The DISCOVER Study
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT07390643 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants.
The verdict
NCT07390643, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Interventions
- DEVICE GRAIL Galleri MCED test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07390643
The ClinicalTrials.gov registry entry for NCT07390643 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRAIL Galleri MCED test is the first listed.
NCT07390643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07390643 about?
NCT07390643 is a clinical study titled "The DISCOVER Study". The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
What is the current status of trial NCT07390643?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2026-07. Estimated completion is 2028-01-31.
What interventions are being tested in trial NCT07390643?
The interventions under investigation include: GRAIL Galleri MCED test (DEVICE).
Who is sponsoring clinical trial NCT07390643?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.